By Giuseppe Fiorentino published in The Lancet September 9, 2021 below with analysis of the article & research by Chris Masterjohn, PhD below and commentary by Mark Bricca, ND "Based on an interim analysis recently published in a journal affiliated with...
Considerations in boosting COVID-19 vaccine immune responses
By Philip R Krause Originally published September 13, 2021 in The Lancet A new wave of COVID-19 cases caused by the highly transmissible delta variant is exacerbating the worldwide public health crisis, and has led to consideration of the potential need for, and...
Considerations in boosting COVID-19 vaccine immune responses
By Philip R Krause, MD A new wave of COVID-19 cases caused by the highly transmissible delta variant is exacerbating the worldwide public health crisis, and has led to consideration of the potential need for, and optimal timing of, booster doses for vaccinated...
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
Published in EClinicalMedicine by The Lancet ~ May 1, 2021 ~ by Laith J. Abu-Raddad, et al. Abstract Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns. SARS-CoV-2...
The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study
https://www.covidstrategies.org/the-impact-of-the-covid-19-pandemic-on-cancer-deaths-due-to-delays-in-diagnosis-in-england-uk-a-national-population-based-modelling-study/https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30388-0/fulltext Originally published by: The Lancet Author: Camille Maringe, et al. Date: 7/20/2020 Categories: Integrative Therapies,Treatment,Ivermectin